Find Clinical Trials

201 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL2-44121-005	Effects of three oral dosages of S 44121 on cardiac arrhythmia during exercise testing in…	S044121	Phase 2	Cardiovascular Diseases
CL2-44121-004	Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac…	S044121	Phase 2	Cardiovascular Diseases
CL2-44121-003	Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac…	S044121	Phase 2	Cardiovascular Diseases
CL2-38844-010	Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844…	S038844	Phase 2	Cardiovascular Diseases
CL2-38093-012	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus…	S038093	Phase 2	Neuropsychiatric Diseases
CL2-38093-011	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus…	S038093	Phase 2	Neuropsychiatric Diseases
CL2-38093-009	Safety and efficacy of S 38093 and donepezil, during 4 weeks, in patients with mild…	S038093	Phase 2	Neuropsychiatric Diseases
CL2-38093-005	Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer’s Disease.…	S038093	Phase 2	Neuropsychiatric Diseases
CL2-33138-011	A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety…	S033138	Phase 2	Neuropsychiatric Diseases
CL2-33138-007	Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms:…	S033138	Phase 2	Neuropsychiatric Diseases
CL2-20098-075	Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-20098-072	Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-20098-067	Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-20098-040	Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-18986-009	Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild…	S018986	Phase 2	Neuropsychiatric Diseases
CL2-18886-031	Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose…	TERUTROBAN, S018886	Phase 2	Metabolism
CL2-18886-026	Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid…	TERUTROBAN, S018886	Phase 2	Cardiovascular Diseases
CL2-16257-101	Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-099	Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-096	Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid)…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-095	Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-090	Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-088	Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-073	Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-062	Evaluation of the effects of 3 successive oral dosages (2.5, 5, 7.5 mg b.i.d.) of…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases